277 related articles for article (PubMed ID: 27889751)
1. Targeted Therapy of Head and Neck Cancer.
Rieke DT; Klinghammer K; Keilholz U
Oncol Res Treat; 2016; 39(12):780-786. PubMed ID: 27889751
[TBL] [Abstract][Full Text] [Related]
2. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
5. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
6. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
7. Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.
Juergens RA; Bratman SV; Tsao MS; Laurie SA; Sara Kuruvilla M; Razak AR; Hansen AR
Cancer Treat Rev; 2017 Mar; 54():43-57. PubMed ID: 28192747
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
[TBL] [Abstract][Full Text] [Related]
9. [Research progress of squamous cell carcinoma of head and neck EGFR targeted therapy resistance mechanisms].
Song Q; Li X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(2):184-90. PubMed ID: 25989677
[TBL] [Abstract][Full Text] [Related]
10. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
Isaacsson Velho PH; Castro G; Chung CH
Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions.
Schmitz S; Ang KK; Vermorken J; Haddad R; Suarez C; Wolf GT; Hamoir M; Machiels JP
Cancer Treat Rev; 2014 Apr; 40(3):390-404. PubMed ID: 24176789
[TBL] [Abstract][Full Text] [Related]
13. EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex.
Lei Y; Kansy BA; Li J; Cong L; Liu Y; Trivedi S; Wen H; Ting JP; Ouyang H; Ferris RL
Oncogene; 2016 Sep; 35(36):4698-707. PubMed ID: 26876213
[TBL] [Abstract][Full Text] [Related]
14. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
[TBL] [Abstract][Full Text] [Related]
15. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
[TBL] [Abstract][Full Text] [Related]
16. EGFR-targeted therapies in the post-genomic era.
Xu MJ; Johnson DE; Grandis JR
Cancer Metastasis Rev; 2017 Sep; 36(3):463-473. PubMed ID: 28866730
[TBL] [Abstract][Full Text] [Related]
17. Integration of molecular targeted therapy with radiation in head and neck cancer.
Du Y; Peyser ND; Grandis JR
Pharmacol Ther; 2014 Apr; 142(1):88-98. PubMed ID: 24280066
[TBL] [Abstract][Full Text] [Related]
18. Molecularly targeted therapies in head and neck cancers.
Sawicki M; Szudy A; Szczyrek M; Krawczyk P; Klatka J
Otolaryngol Pol; 2012; 66(5):307-12. PubMed ID: 23036118
[TBL] [Abstract][Full Text] [Related]
19. Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.
Ugurluer G; Ozsahin M
Expert Opin Investig Drugs; 2014 Dec; 23(12):1637-54. PubMed ID: 25134724
[TBL] [Abstract][Full Text] [Related]
20. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]